US Compounding, a Subsidiary of Adamis Pharmaceuticals, Develops a Unique Compound to Manage Ulcers in Horses
December 06 2017 - 4:29PM
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Adamis”) today
announced that its subsidiary, US Compounding, has developed a
unique compound to manage ulcers in horses. Ulcers are common
in the majority of horses that are subject to stress.
Examples of horses under stress include race horses, endurance
horses, dressage horses, hunters, jumpers, 3-day eventers and any
type of rodeo horse. In general, horses that are in active
training tend to have a prevalence of ulcers in the range of 90 to
95%. Historically, ulcers have been known to negatively
affect feeding habits and performance on the track.
A study, utilizing US Compounding’s unique drug formulation, was
conducted in approximately 50 race horses. Gastric endoscopy
was performed at day 0 and any time between days 14 and 21.
Drug was administered after the first endoscopy as a paste given
orally for 30 days. Endoscopic improvement was seen as early
as 14 days. In greater than 95% of the horses the ulcers were
shown to be clinically healed, as confirmed by endoscopy, with a
reduction in gastric ulcer recovery times. A patent
application covering this unique compounded product has been filed
by the Company. In addition, a manuscript is in
preparation.
Two horses that were receiving US Compounding’s product recently
competed in the 2017 Breeders Cup and both placed first in their
respective races. Ralph Nicks, trainer for Caledonia Road,
stated, “To compete at the elite level your horses must maintain
top form. US Compounding products are an integral part of
ensuring that our horses do just that”. John Kimmel, trainer
for Bar of Gold stated, “US Compounding is an important piece of
our team’s continued success. Their products help maintain a
level of wellness needed to compete at the top level.”
Dr. Dennis J. Carlo, President and CEO of Adamis stated, “This
new compound is the first in the expansion of our veterinary
product line. As a side note, since the Breeders Cup, two
additional horses using our products won their respective races,
one setting a track record.”
About Adamis Pharmaceuticals
Adamis Pharmaceuticals Corporation is a specialty
biopharmaceutical company focused on developing and commercializing
products in the therapeutic areas of respiratory disease and
allergy. The company’s first product, Symjepi (epinephrine)
Injection 0.3mg, was approved in June 2017 for use in the emergency
treatment of acute allergic reactions, including anaphylaxis.
Adamis’ product pipeline includes a naloxone injection product
candidate using the SymjectTM syringe drug delivery platform, a HFA
metered dose inhaler and dry powder inhaler products for the
treatment of bronchospasm and asthma.
The company’s U.S. Compounding, Inc. (USC) subsidiary, which is
registered as a drug compounding outsourcing facility under Section
503B of the U.S. Food, Drug & Cosmetic Act and the U.S. Drug
Quality and Security Act, compounds sterile prescription drugs, and
certain nonsterile drugs, to patients, physician clinics,
hospitals, surgery centers and other clients throughout most of the
United States.
Adamis Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. These statements relate to future events or future
results of operations, including, but not limited to the following
statements: the outcome of any further studies or trials relating
to the USC compound to manage ulcers in horses; the company’s
ability to successfully develop additional veterinary products and
product candidates; the company's beliefs concerning the ability of
its products and product candidates to compete successfully in the
market; and the company's beliefs concerning the safety and
effectiveness of its products and product candidates. There
are no assurances concerning the commercial success of the
company’s veterinary compound for management of ulcers in
horses. In addition, results in any subsequent studies
concerning the ulcer compound for horses may be different from the
study described in this press release. These statements are
only predictions and involve known and unknown risks, uncertainties
and other factors, which may cause Adamis' actual results to be
materially different from those contemplated by these
forward-looking statements. Certain of these risks,
uncertainties, and other factors are described in greater detail in
Adamis’ filings from time to time with the SEC, which Adamis
strongly urges you to read and consider, all of which are available
free of charge on the SEC's web site
at http://www.sec.gov. Any forward-looking statement in
this press release speaks only as of the date on which it is
made. Except to the extent required by law, Adamis expressly
disclaims any obligation to update any forward-looking
statements.
Contact:Mark Flather Senior Director, Investor
Relations& Corporate Communications Adamis Pharmaceuticals
Corporation (858) 412-7951mflather@adamispharma.com
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Apr 2023 to Apr 2024